genOway SA ( (FR:ALGEN) ) has provided an update.
In 2024, genOway achieved a 10% revenue growth to €22.1 million, demonstrating strong resilience in a contracting market and driven by its catalog model sales. The company’s ROUTE50+ strategic plan aims to expand its commercial team and market presence, particularly in the U.S. and Europe, with initiatives such as opening a structure in Japan, enhancing marketing efforts, and launching new models in immuno-oncology and inflammatory processes, signaling a robust outlook for continued growth and profitability.
More about genOway SA
Founded in 1999, genOway is a company based in Lyon, France, specializing in the design, development, and commercialization of genetically modified preclinical models, including mice, rats, and cell lines, to better mimic humans and their diseases for pharmaceutical research. With operations in over 28 countries and clients including prestigious academic research laboratories and top pharmaceutical companies, genOway’s mission is to provide predictive preclinical solutions for the selection of effective and safe drug candidates.
Current Market Cap: $32.38M
See more data about ALGEN stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com